• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组人促红细胞生成素如何影响肌酐清除率?

How does rHuEPO effect D/P creatinine ratios?

作者信息

Richmond D, Broyan P, Shea S, Reft C, Poseno M, Gimenez L F

机构信息

Good Samaritian Hospital, Baltimore MD.

出版信息

Adv Perit Dial. 1992;8:457-9.

PMID:1361847
Abstract

Initially starting CAPD patients on EPO was concerning after hearing reports of hemodialysis patients stating that they "may need more dialysis". The rationale given was that with a higher hematocrit the percentage of plasma in whole blood would decrease, leading to an increase of red cell mass. This decreased plasma volume and increased viscosity would lead to a slower blood flow ultimately resulting in less efficient dialysis. Assessing CAPD patients' peritoneal efficiency was the next step. We obtained pre and post-EPO PETs and evaluated. The initial results showed that D/P creatinine ratios were dropping as our Hcts increased, and ultrafiltration results projected an improvement. What remained unanswered was what took place over extended periods of time on EPO therapy. We examined twelve patients over a period of 27 months. Each patient received 4 exchanges per day using 1500 to 2500 volume. PET tests were performed on each patient prestudy, and at months three, six, and 25-27. Initially each patient received EPO 4000 units, 3/week, SQ. EPO easily increased and maintained our patients' hematocrits within 12 weeks after starting the study. D/P creatinine ratios initially dropped but as our study continued there was a return of D/P creatinine ratios to 6% greater than baseline. One report suggests that EPO may have a direct vasoconstricting effects on blood vessels caused by the stimulation of calcium toward the cell. Vasoconstriction of the vessels would lead to a decrease in exchangeable surface area resulting in a decreased D/P creatinine ratio.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在听闻血液透析患者称“可能需要更多透析”的报告后,最初让持续性非卧床腹膜透析(CAPD)患者使用促红细胞生成素(EPO)令人担忧。给出的理由是,随着血细胞比容升高,全血中血浆的百分比会降低,导致红细胞量增加。血浆量减少和粘度增加会导致血流减慢,最终导致透析效率降低。下一步是评估CAPD患者的腹膜效率。我们获取了使用EPO前后的腹膜平衡试验(PET)结果并进行评估。初步结果显示,随着血细胞比容升高,肌酐清除率D/P比值下降,超滤结果显示有改善。仍未得到解答的是,长期进行EPO治疗会发生什么情况。我们在27个月的时间里对12名患者进行了检查。每位患者每天进行4次换液,换液量为1500至2500毫升。在研究前以及第3、6和25 - 27个月对每位患者进行PET检测。最初,每位患者每周皮下注射3次EPO,每次4000单位。在开始研究后的12周内,EPO很容易就提高并维持了我们患者的血细胞比容。肌酐清除率D/P比值最初下降,但随着研究的继续,肌酐清除率D/P比值回升至比基线高6%。一份报告表明,EPO可能通过刺激钙离子向细胞内移动而对血管产生直接的血管收缩作用。血管收缩会导致可交换表面积减少,从而使肌酐清除率D/P比值降低。(摘要截选至250字)

相似文献

1
How does rHuEPO effect D/P creatinine ratios?重组人促红细胞生成素如何影响肌酐清除率?
Adv Perit Dial. 1992;8:457-9.
2
Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.
Adv Perit Dial. 1992;8:467-70.
3
Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.皮下注射促红细胞生成素治疗持续性非卧床腹膜透析患者贫血的间歇性给药方案
Adv Perit Dial. 1993;9:331-5.
4
Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity.持续性非卧床腹膜透析患者对促红细胞生成素的中期反应:促红细胞生成素血浆水平的影响及其对腹膜转运能力的作用
Adv Perit Dial. 1991;7:296-300.
5
The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.静脉注射铁剂单独或联合小剂量促红细胞生成素在快速纠正透析前慢性肾衰竭贫血中的作用。
Clin Nephrol. 2001 Mar;55(3):212-9.
6
[The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].[血液透析和持续性非卧床腹膜透析对肾性贫血的影响]
Srp Arh Celok Lek. 1997 May-Jun;125(5-6):163-7.
7
Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.腹膜转运状态对持续性非卧床腹膜透析患者动脉粥样硬化/炎症的影响。
J Ren Nutr. 2005 Oct;15(4):427-34. doi: 10.1053/j.jrn.2005.07.007.
8
Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.在接受重组人促红细胞生成素治疗的持续性非卧床腹膜透析或持续性循环腹膜透析患者中使用大剂量腹腔内右旋糖酐铁。
Adv Perit Dial. 1999;15:60-4.
9
Recombinant human erythropoietin (rHuEPO) therapy has no effect on peritoneal transport in CAPD patients: a short-term study.重组人促红细胞生成素(rHuEPO)治疗对持续性非卧床腹膜透析(CAPD)患者的腹膜转运无影响:一项短期研究。
Adv Perit Dial. 1998;14:11-3.
10
Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析患者身体尺寸指数、残余肾功能及腹膜转运特性的长期随访
Adv Perit Dial. 2009;25:155-64.